293 related articles for article (PubMed ID: 24402662)
1. [The use of tolvaptan in a case of severe hyponatriemia in SIADH during meningitis].
Rollino C; Balbiano R; Caramello P; Roccatello D
G Ital Nefrol; 2013; 30(6):. PubMed ID: 24402662
[TBL] [Abstract][Full Text] [Related]
2. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
[TBL] [Abstract][Full Text] [Related]
3. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
[TBL] [Abstract][Full Text] [Related]
5. Effect of tolvaptan on hyponatremia in a dog with syndrome of inappropriate secretion of antidiuretic hormone.
Yamamoto H; Kimura K; Horikirizono H; Tamura Y; Kambayashi S; Baba K; Okuda M; Mizuno T; Igase M
J Vet Med Sci; 2023 Oct; 85(10):1047-1051. PubMed ID: 37587049
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH.
Soupart A; Coffernils M; Couturier B; Gankam-Kengne F; Decaux G
Clin J Am Soc Nephrol; 2012 May; 7(5):742-7. PubMed ID: 22403276
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.
Bordi P; Tiseo M; Buti S; Regolisti G; Ardizzoni A
Tumori; 2015 Apr; 101(2):e51-3. PubMed ID: 25702667
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
Jamookeeah C; Robinson P; O'Reilly K; Lundberg J; Gisby M; Ländin M; Skov J; Trueman D
BMC Endocr Disord; 2016 May; 16(1):22. PubMed ID: 27184496
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database.
Hagiwara D; Matsukawa M; Tasaki J; Nakamura Y; Arima H
Endocr J; 2023 Dec; 70(12):1195-1205. PubMed ID: 37914256
[TBL] [Abstract][Full Text] [Related]
10. Prompt efficacy of tolvaptan in treating hyponatremia of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) closely associated with rupture of a gastric artery aneurysm.
Yamashita T; Yoshida M; Yamada H; Asano T; Aoki A; Ikoma A; Kusaka I; Kakei M; Ishikawa SE
Intern Med; 2014; 53(8):845-9. PubMed ID: 24739604
[TBL] [Abstract][Full Text] [Related]
11. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
Ramamohan V; Mladsi D; Ronquest N; Kamat S; Boklage S
Hosp Pract (1995); 2017 Aug; 45(3):111-117. PubMed ID: 28449624
[TBL] [Abstract][Full Text] [Related]
12. Low-dose tolvaptan for the treatment of hyponatremia in the syndrome of inappropriate ADH secretion (SIADH).
Harbeck B; Lindner U; Haas CS
Endocrine; 2016 Sep; 53(3):872-3. PubMed ID: 26961548
[No Abstract] [Full Text] [Related]
13. Tolvaptan for Treatment of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in a Child with Corpus Callosum Agenesis.
Meena AK; Nanda PM; Sharma R; Chakrabarty B; Gulati S
Indian J Pediatr; 2024 Feb; 91(2):188-190. PubMed ID: 36757652
[TBL] [Abstract][Full Text] [Related]
14. [Lower doses of tolvaptan in hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion].
Sánchez Sobrino P; Fernández Catalina P; Lorenzo Solar M; Rego Iraeta A
Med Clin (Barc); 2015 Aug; 145(3):138-9. PubMed ID: 25543222
[No Abstract] [Full Text] [Related]
15. Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion.
Gargani L; Schmidt PH; Gheorghiade M
Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1505-13. PubMed ID: 22103869
[TBL] [Abstract][Full Text] [Related]
16. Tolvaptan for SIADH in Myelodysplastic Syndrome with Blast Crisis.
Mali P; Muduganti SR; Mujibur R; Murali N
WMJ; 2015 Apr; 114(2):66-8. PubMed ID: 26756059
[TBL] [Abstract][Full Text] [Related]
17. Tolvaptan Treatment in Children with Chronic Hyponatremia due to Inappropriate Antidiuretic Hormone Secretion: A Report of Three Cases.
Tuli G; Tessaris D; Einaudi S; De Sanctis L; Matarazzo P
J Clin Res Pediatr Endocrinol; 2017 Sep; 9(3):288-292. PubMed ID: 28515029
[TBL] [Abstract][Full Text] [Related]
18. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan.
De Las Peñas R; Ponce S; Henao F; Camps Herrero C; Carcereny E; Escobar Álvarez Y; Rodríguez CA; Virizuela JA; López López R
Support Care Cancer; 2016 Jan; 24(1):499-507. PubMed ID: 26431960
[TBL] [Abstract][Full Text] [Related]
19. [Vasopressin receptor antagonists: the vaptans].
Villabona C
Endocrinol Nutr; 2010 May; 57 Suppl 2():41-52. PubMed ID: 21130961
[TBL] [Abstract][Full Text] [Related]
20. Management of euvolemic hyponatremia attributed to SIADH in the hospital setting.
Peri A; Giuliani C
Minerva Endocrinol; 2014 Mar; 39(1):33-41. PubMed ID: 24513602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
